Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.
Int Rev Neurobiol. 2011;101:65-94. doi: 10.1016/B978-0-12-387718-5.00004-3.
In the postgenome era, proteomics has arisen as a promising tool for more complete comprehension of diseases and for biomarker discovery. Some of these objectives have already been partly achieved for illnesses such as cancer. In the case of psychiatric conditions, however, proteomic advances have had a less profound impact. Here, we outline the necessity of improving and applying proteomic methods for biomarker discovery and validation in the field of psychiatric disorders. While proteomic-based applications in neurosciences have increased in accuracy and sensitivity over the past 10 years, the development of orthogonal validation technologies has fallen behind. These issues are discussed along with the importance of integrating systems biology approaches and combining proteomics with other research approaches. The future development of such technologies may put proteomics closer to clinical applications in psychiatry.
在后基因组时代，蛋白质组学已成为更全面地理解疾病和发现生物标志物的一种很有前途的工具。对于癌症等疾病，已经部分实现了这些目标。然而，在精神疾病的情况下，蛋白质组学的进展影响较小。在这里，我们概述了在精神障碍领域改进和应用蛋白质组学方法进行生物标志物发现和验证的必要性。尽管过去 10 年来基于蛋白质组学的神经科学应用在准确性和灵敏度方面有所提高，但正交验证技术的发展却落后了。本文讨论了这些问题，并强调了整合系统生物学方法以及将蛋白质组学与其他研究方法相结合的重要性。这些技术的未来发展可能会使蛋白质组学更接近精神病学的临床应用。
